Chad E. Bennett

Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats

J. Byrd, S. Kulp, Dasheng Wang, 2020, The AAPS Journal.

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer

B. Ramaswamy, J. Datta, R. Ganju, 2022, bioRxiv.

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer

B. Ramaswamy, J. Datta, R. Ganju, 2022, Frontiers in Oncology.

A Novel Estrogen Receptor β Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition

Qi-En Wang, Junran Zhang, S. Patnaik, 2022, Cancers.

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Logan A. Walker, J. Byrd, R. Bundschuh, 2021, Blood.

Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists.

Dasheng Wang, P. Anzenbacher, H. Radomska, 2021, Journal of medicinal chemistry.

Arrowtail RNA for Ligand Display on Ginger Exosome-like Nanovesicles to Systemic Deliver siRNA for Cancer Suppression

Peixuan Guo, Huang-Ge Zhang, Hongran Yin, 2018, Scientific Reports.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma

P. Houghton, Jiayuh Lin, Hui Xiao, 2017, PloS one.